Klebsiella pneumoniae poses significant global health challenges due to its increasing antimicrobial resistance (AMR). The emergence of multidrug-resistant (MDR) and carbapenem-resistant strains has limited treatment options, making infections difficult to control. This pathogen utilizes several mechanisms, including extended-spectrum β-lactamase (ESBL) production and efflux pumps, contributing to its resistance. Novel therapeutic approaches, such as bacteriophage therapy, CRISPR-Cas systems, and antimicrobial peptides, are being explored to combat AMR. Additionally, targeting virulence factors and biofilm formation holds promise for developing alternative strategies, providing a new frontier in tackling this formidable pathogen.